Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?
Medical Sciences · 2026
DOI: 10.3390/medsci14050534 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, 2026. Verfasst von Ariadni Fouza und 1 weiteren Autor:innen. Beteiligte Einrichtung: 5th Surgical Department, Hippokratio General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunity, Humoral, Graft Rejection, Allografts. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody-mediated rejection (AMR) remains a major cause of kidney allograft injury and loss. Although donor-specific antibodies against human leukocyte antigens (HLA-DSAs) are central to humoral alloimmunity, they do not explain all cases of microvascular inflammation or graft dysfunction. This review critically evaluates non-HLA antibodies as potential mediators of allograft injury and markers of dysregulated humoral immunity by integrating functional, experimental, clinicopathological, and clinical evidence. Receptor-targeting antibodies, especially those against the angiotensin II type 1 receptor (AT1R) and the endothelin-1 type A receptor (ETAR), have the strongest evidence for direct pathogenicity. Antibodies against major histocompatibility complex class I-related chain A (MICA) and glutathione S-transferase theta-1 (GSTT1) reflect non-HLA alloimmunity, whereas antibodies targeting perlecan-derived LG3, vimentin, and injury-associated antigens may arise through secondary autoimmunity and mark broader humoral activation. We propose that selected pathogenic non-HLA antibodies participate in a feed-forward cycle of graft injury, antigen exposure, epitope spreading, and humoral amplification, although this model requires longitudinal validation. Crucially, non-HLA antibody positivity alone should neither establish AMR nor guide antibody-specific treatment. Its interpretation should be target-specific and integrated with HLA-DSAs, histopathology, molecular findings, graft function, and evidence of immune activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 5th Surgical Department, Hippokratio General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- Department of Transplant Surgery, Center for Research and Innovation in Solid Organ Transplantation, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
ORCID-Profile: Maria Daoudaki
Zitieren
APA
Fouza, A., & Daoudaki, M. (2026). Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?. Medical Sciences. https://doi.org/10.3390/medsci14050534
Vancouver
Fouza A, Daoudaki M. Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?. Medical Sciences. 2026. doi:10.3390/medsci14050534
BibTeX
@article{Fouza2026,
author = {Fouza, Ariadni and Daoudaki, Maria},
title = {Non-HLA Antibodies in Kidney Transplantation: Mediators of Allograft Injury or Markers of Dysregulated Humoral Immunity?},
journal = {Medical Sciences},
year = {2026},
doi = {10.3390/medsci14050534}
}
EUVIMED